Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases

J Rheumatol. 2022 Mar;49(3):334-335. doi: 10.3899/jrheum.210863. Epub 2022 Jan 15.

Authors

Marco Fornaro¹, Vincenzo Venerito¹, Florenzo Iannone², Fabio Cacciapaglia¹

Affiliations

¹ Rheumatology Unit, Department of Emergency and Organ Transplantation, Bari, Italy.
² Rheumatology Unit, Department of Emergency and Organ Transplantation, Bari, Italy. [email protected].

PMID: 35033998
DOI: 10.3899/jrheum.210863

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Viral
BNT162 Vaccine
COVID-19 Vaccines / adverse effects
COVID-19* / prevention & control
Humans
RNA, Messenger
Recurrence
Rheumatic Diseases* / drug therapy
SARS-CoV-2
Vaccination

Substances

Antibodies, Viral
COVID-19 Vaccines
RNA, Messenger
BNT162 Vaccine